share_log

Oppenheimer Maintains Outperform on Corvus Pharma, Lowers Price Target to $7

Moomoo 24/7 ·  Mar 20 07:14

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment